Press Releases

Press Release 4 

LONDON, Nov. 26, 2020 /PRNewswire/ -- Haoma Medica announced today the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis. 

The first-in-human trial initiated last year in healthy adults studied single and multiple doses of NaQuinate. The primary objective was to assess the safety, tolerability and pharmacokinetics.

''We are delighted that the first-in-human study has completed its last dosing. There were no significant safety or tolerability concerns up to the highest doses tested which underlines our expectation that NaQuinate is safe and well tolerated,'' said Dr Cenk Oguz, Haoma Medica's Chief Medical Officer.

'Our pre-clinical research has revealed an exciting feature of NaQuinate where it appears to have the capacity to work in harmony with the body's natural response to weight bearing exercise to synergistically enhance bone formation when and where required – now that would be a 'smart' drug,' said Dr Steve Deacon, Haoma Medica's CEO. 'Together with the safety data from this first-in-human study, this supports the potential that NaQuinate treatment could provide a safe, novel and smart therapeutic approach to bone disorders like osteoporosis and better maintain healthy skeletal aging.

 

About NaQuinate

Previous studies have shown NaQuinate to protect against reduction in bone quality and quantity that occurs in response to ovariectomy in rodent models.  In a mechanical mouse loading model, a surrogate for weight-bearing exercise, NaQuinate synergistically enhanced the body's normal response to loading by forming bone, targeting relevant cortical bone regions. This synergistic interaction between NaQuinate and mechanical loading suggests the functional use of bones' mechanostat, a term which describes how mechanical loading affects bone structure, in the regulation of bone mass and architecture. NaQuinate is currently being evaluated using a curative model of osteoporosis versus a bisphosphonate and a loading model versus an anabolic; results are expected early next year.

About Osteoporosis

Osteoporosis is a silent disease often not presenting with any signs or symptoms until a fracture occurs. It thus remains an underdiagnosed and undertreated disease.

Osteoporosis results in bone loss and changes in bone quality and strength that occurs through the normal aging process leading to fragile bones. Fragile bones lead to fractures, which progresses into a downward spiral of disability, loss of independence and increased mortality with considerable social and economic burden. Fragility fractures are a major obstacle to healthy aging. Worldwide, there is a fragility fracture every 3 seconds.

According to the International Osteoporosis Foundation, about 200 million suffer from the disease worldwide. A combined lifetime risk of fractures is 40% and is equivalent to the risk of cardiovascular disease. In women over 45 years of age, osteoporosis results in more time in hospitals that many other diseases such as breast cancer, heart attacks, and diabetes.

About Haoma Medica 

Haoma Medica is a clinical-stage biotechnology company focused on the development of therapeutics to maintain bone and vascular health.

For more information, please visit www.haomamedica.com

 

Investor Relations Contact:

Name: Carmen Greco                                                   
e-mail: carmen.greco@haomamedica.com         

 

Press Release: https://www.prnewswire.com/news-releases/haoma-medica-completes-first-in-human-trial-for-naquinate-a-novel-treatment-in-development-for-osteoporosis-301181026.html

Press Release 3 

Haoma Medica Announces Plenary Presentation for NaQuinate, a Potential Novel Treatment for Osteoporosis, at ASBMR 2020 Annual Meeting

 

London, UK, 11 September 2020 - Haoma Medica announced a presentation made today at the 2020 American Society for Bone and Mineral Research:

Dr Andrew Pitsillides, Professor of Skeletal Dynamics at the Royal Veterinary College, London presented: 'NaQuinate: A Drug that Selectively Synergizes with Mechanical Loading Stimuli In Vivo to Generate Greater Cortical Bone Mass and Architectural Modifications’.


Previous studies have shown NaQuinate, a naphthoquinone carboxylic acid, to protect against reduction in bone quality and quantity occurring in response to ovariectomy in rat and mouse models. In the data presented today using an applied mechanical mouse loading model, NaQuinate synergized the body’s normal response to loading (a surrogate for greater weight-bearing exercise) to generate significant increases in cortical bone mass (increased cross sectional area, reductions in cortical porosity) and J-score (predictor of bone strength) compared to loading alone; the combined effect of loading and NaQuinate was much greater than additive. The bone studied here was the tibia in the leg, one of the largest bones in the body and where cortical bone is the core component.

 

‘There are 3 ways to maintain bone quality and strength to resist fracture - stop bone loss, build mass and enhance the topographical changes to optimize and enhance weight-bearing roles. It may be that NaQuinate can achieve a balance of all three to treat osteoporosis and better maintain healthy aging,’ said Professor Andrew Pitsillides, presenting author.

 

NaQuinate as a treatment for post-menopausal women with osteoporosis, is an investigational product, currently in Phase I clinical trials and its safety and efficacy have not been established.

 

About Osteoporosis and Cortical Bone


Cortical bone is the dense outer shell of bone that forms a protective layer around the internal cavity. It is imperative to body structure and weight bearing because of its high resistance to bending and twisting.

 

Osteoporosis is a silent disease often not presenting with any symptoms until a fracture occurs. It thus remains an underdiagnosed and undertreated disease.

 

Osteoporosis results in bone loss and changes in bone quality and strength that occurs through the normal aging process leading to fragile bones. Fragile bones lead to fractures, which progresses into a downward spiral of disability, loss of independence and increased mortality with considerable social and economic burden. Fragility fractures are therefore a major obstacle to healthy aging. Worldwide there is a fragility fracture every 3 seconds.

 

According to the National Osteoporosis Foundation about 54 million Americans have osteoporosis with studies suggesting one in two women and one in four men aged 50 and older will have a fragility fracture (or low impact fracture often occurring from a minor bump or fall from standing height) within their life.

 

About Haoma Medica

Haoma Medica Ltd is a clinical-stage biotechnology company focused on the development of therapeutics to maintain bone and vascular health. For more information, please visit www.haomamedica.com

 

Investor Relations Contact

Name: Carmen Greco                                              

e-mail: carmen.greco@haomamedica.com          

Phone: +44(0)207 629 1954       

 

Release:   https://www.prnewswire.com/news-releases/haoma-medica-announces-plenary-presentation-for-naquinate-a-potential-novel-treatment-for-osteoporosis-at-asbmr-2020-annual-meeting-301128008.html

Press Release 2
RVC researcher presents poster on a potentially exciting new treatment for skeletal disorders

 

London, UK, 10 September 2020 - Dr Andrew Pitsillides, Professor of Skeletal Dynamics at the Royal Veterinary College (RVC) has today presented a poster at the American Society of Bone and Mineral Research (ASBMR) highlighting a potential new treatment for skeletal disorders such as osteoporosis.

Osteoporosis affects over 3 million people in the UK and more than 500,000 people receive hospital treatment for bones that break after falling from standing height or less every year due to the condition. The condition also creates a significant social and economic burden, with fractures often leading to a downward spiral of disability, loss of independence and increased mortality more...

Release: https://www.rvc.ac.uk/research/programmes/comparative-physiology-and-medicine/news/rvc-researcher-presents-poster-on-a-potentially-exciting-new-treatment-for-skeletal-disorders

Press Release 1
Haoma Medica to Present Scientific Data on NaQuinate, a Potential New Treatment for Osteoporosis, at the Upcoming ASBMR 2020 Annual Meeting

 

London, UK, 10 September 2020 - Haoma Medica announced today that it will present three scientific posters on NaQuinate at the upcoming American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting, which this year takes place as a virtual event from 11-15 September.

NaQuinate, a naphthoquinone carboxylic acid, is being developed as a novel orally administered therapeutic for osteoporosis. ‘’Haoma Medica is dedicated to investigating new ways to treat osteoporosis and maintain healthy aging and we look forward to sharing new pre-clinical data for NaQuinate at this key meeting with bone health experts’’ said Prof Stephen Hodges, Haoma Medica’s Chief Scientific Officer more...

Release: https://www.prnewswire.com/news-releases/haoma-medica-to-present-scientific-data-on-naquinate-a-potential-new-treatment-for-osteoporosis-at-asbmr-2020-annual-meeting-301127252.html?tc=eml_cleartime

Contact Information

Office Phone  (+44) 0207 629 1954

LBIC Phone    (+44) 0189 526 5540

Emails

info@haomamedica.com

stephen.hodges@haomamedica.com (CSO)

stephen.deacon@haomamedica.com (CEO)

carmen.greco@haomamedica.com (CFO)

cenk.oguz@haomamedica.com (CMO)

Mailing Address

Haoma Medica Ltd.

c/o London BioScience Innovation Centre

2 Royal College Street 

London, England

United Kingdom

NW1 0NH

LinkedIn Haoma Medica

Company Registration GB No. 06784000